ストックスクリーナーアプリを入手
218.27
0.60%
-1.31
前日終値:
$219.58
開ける：
$220.44
24時間の取引高:
861.12K
Relative Volume:
0.61
時価総額：
$31.49B
収益：
$5.54B
当期純損益:
$1.52B
株価収益率:
21.04
EPS:
10.3734
ネットキャッシュフロー:
$1.74B
1週間 パフォーマンス:
-4.41%
1か月 パフォーマンス:
-2.92%
6か月 パフォーマンス:
-9.11%
1年 パフォーマンス:
-20.52%
1日の値動き範囲:
$215.97
$221.29
1週間の範囲:
$215.80
$226.66
52週間の値動き範囲:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Compare RMD vs ISRG, BDX, ALC, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
218.27 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
369.15 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
177.85 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.03 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
32.53 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | JP Morgan | Overweight |
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
ResMed Stock Is Up 13% in Three Months, The Buyback Is Doing the Heavy Lifting. Here’s What It Could Be Worth Before 2027. - TIKR.com
ResMed Inc. stock extends eight-day slide as market value drops - ad-hoc-news.de
ResMed Stock Slides 8.6% Over 8 Straight Down Days - Trefis
ResMed stock heads into the open after a 0.2% dip - ad-hoc-news.de
Is ResMed (ASX:RMD) the Steadier Name in Healthcare? - Kalkine Media
ResMed Inc. stock dips as CEO share sale draws investor attention - ad-hoc-news.de
ResMed CEO Michael J. Farrell Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
ResMed CEO Michael Farrell sells $1.11 million of company shares - Investing.com
ResMed: A Significant Upside Despite The Perceived Risk (NYSE:RMD) - Seeking Alpha
ResMed CEO Michael Farrell sells $1.11 million of company shares By Investing.com - Investing.com India
ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares - MarketBeat
Are Resmed CDI (ASX:RMD) shares good value in 2026? - Rask Media
Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating - marketscreener.com
Amundi Trims Holdings in ResMed Inc. $RMD - MarketBeat
ResMed stock heads into the open after a 3.3 percent slide - ad-hoc-news.de
Will ResMed Sleep Research Sharpen Its Case (ASX:RMD)? - Kalkine Media
ResMed Inc. stock falls after valuation warning but fundamentals stay solid - ad-hoc-news.de
ResMed Inc. $RMD Shares Purchased by California State Teachers Retirement System - MarketBeat
ResMed (ASX:RMD) Shares Retreat While FY26 Growth Remains in Focus - Kalkine
Resmed Inc Draws Eyes to Healthcare Pathway (ASX:RMD) - Kalkine Media
Is ResMed Inc (RMD) a Bargain After 3.2% Drop? GF Value Says Und - GuruFocus
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Farrell Peter C Disposes of 970 Shares in ResMed at $234.73 Each on September 2, 2026 - Kalkine Media
ResMed Inc. stock slips as Astral halt and GLP-1 worries weigh on sentiment - ad-hoc-news.de
Insider at ResMed (NYSE: RMD) lines up a million-dollar stock sale - Stock Titan
Resmed Inc Stock (RMD) Moved Down by 3.15% on Sep 8: What Investors Need To Know - TradingKey
Saudi Central Bank Increases Position in ResMed Inc. $RMD - MarketBeat
Wellington Management Group LLP Grows Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC - MarketBeat
ResMed Inc. stock heads into the open after a 0.4% dip - ad-hoc-news.de
Why Is ResMed Inc. (ASX:RMD) Drawing Fresh Attention Among Healthcare Stocks? - Kalkine Media
How is ResMed (ASX:RMD) framing its sleep research push? - Kalkine Media
ResMed Inc. stock gains on FY2026 growth and buyback launch - ad-hoc-news.de
ResMed Inc Reports August 2026 CHESS Depositary Interests and Securities Update - Kalkine Media
Paralel Advisors LLC Purchases Shares of 10,293 ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Navigating a 7.78% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
ResMed Inc. $RMD Shares Acquired by Giverny Capital Inc. - MarketBeat
ResMed Inc Discloses August 2026 CDI and Securities Statement - Kalkine
Why Is ResMed (ASX:RMD) Sustaining Home-Care Demand? - Kalkine Media
ResMed Director Peter Farrell Sells 970 Shares Under Rule 10b5-1 Plan - Kalkine
ResMed Inc. stock holds above support as fiscal 2026 growth and cautious 2027 outlook shape sentimen - AD HOC NEWS
ResMed Director Peter Farrell Executes Sale of 970 Shares via 10b5-1 Trading Plan - Kalkine Media
ResMed chairman emeritus Peter Farrell sells $227,688 in stock By Investing.com - Investing.com South Africa
ResMed (NYSE:RMD) Director Peter Farrell Sells 970 Shares - MarketBeat
ResMed chairman emeritus Peter Farrell sells $227,688 in stock - Investing.com
ResMed (RMD) director sells shares under trading plan - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc.RMD - PR Newswire
Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating - marketscreener.com
Nykredit A S Acquires New Position in ResMed Inc. $RMD - MarketBeat
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts - ChartMill
Jupiter Topco LLC Takes Position in ResMed Inc. $RMD - MarketBeat
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
0.43%
大文字化:
|
ボリューム (24 時間):